Xlife Sciences AG: Xlife Sciences waives early redemption of the privately placed convertible bond until July 1, 2023
|
This is intended to ensure that the largest amount of shares possible remain tradable and in free float. About Xlife Sciences AG Xlife Sciences AG (m:access: XLS) is a Swiss company with focus on investing in promising technologies in the life science industry. Xlife Sciences AG is building the bridge from research and development to healthcare markets. Together with industrial partners or universities, Xlife Sciences AG leads projects through the proof-of-concept phase after an invention disclosure or start-up. Subsequently, the firm focuses on out-licensing or selling the company, often with a combination of a strategic partnership. Xlife Sciences AG offers its investors direct access to the further development of innovative and future-oriented technologies at a very early stage. End of Media Release Issuer: Xlife Sciences AG Key word(s): Finance
01.07.2020 Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG. |
| Language: | English |
| Company: | Xlife Sciences AG |
| Klausstrasse 19 | |
| 8008 Zürich | |
| Switzerland | |
| Phone: | 0041 44 385 84 60 |
| E-mail: | [email protected] |
| Internet: | www.xlifesciences.ch |
| ISIN: | CH0461929603 |
| WKN: | A2PK6Z |
| Listed: | Regulated Unofficial Market in Frankfurt, Munich |
| EQS News ID: | 1083163 |
| End of News | DGAP Media |
|
|
1083163 01.07.2020
